Skip to NavigationSkip to content

Cellectis appoints Dr Andrew Scharenberg

Published on: 12/07/11

Paris-based genome engineering specialist Cellectis Therapeutics has appointed Dr Andrew Scharenberg as chief scientific officer.

He is an attending physician in Immunology at Seattle Children's Hospital, and Professor of Pediatrics and Immunology at the University of Washington.

Dr Scharenberg is also a principal investigator and co-director of the Northwest Genome Engineering Consortium (NGEC), which is focused on new approaches for treating genetic diseases.

In addition, he is a cofounder and member of the Board of Director's of Pregenen, a biotechnology spin-off from the NGEC, and a strategic partner of Cellectis.

"We are thrilled that Andrew Scharenberg has accepted the post of chief scientific officer of our therapeutic subsidiary," said chief scientific officer of the Cellectis group Frederic Paques. "His experience and energy will push our research teams to achieve their full potential."

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches